|Day Low/High||15.07 / 15.91|
|52 Wk Low/High||13.66 / 33.44|
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.
Vanda's Fanapt is treated roughly in the new psychiatrists' 'bible', further hurting the drug's launch efforts.
Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.
Biotech's first-quarter earnings season kicks off next week. Here are earnings summaries for nine revenue-generating biotech stocks.
Biotech columnist Feuerstein answers readers' questions about Generex, Cell Therapeutics and other stocks.
Expecting limited upside, a call seller boosts volume in Vanda Pharmaceuticals.
A look back at 2009's best- and worst-performing bitoech stocks.
Diedrich Coffee is up 9,580%, RHI Entertainment lands at the bottom, down 96%.
Vanda Pharmaceuticals entered into an exclusive license agreement with Novartis to commercialize and develop schizophrenia drug Fanapt in the U.S. and Canada.
Novartis to pay Vanda up to $465 million for rights to sell schizophrenia drug in US, Canada
Vanda's chances of getting acquired seem to be drying up, according to two analysts.
Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.
Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.
Vanda Pharmaceuticals can't find a buyout partner; Oculus Innovative Sciences backs off drug claims; Sequenom walks back expectations for its Downs syndrome gene test.
For the fourth day in a row, Bank of America remains atop TheStreet.com's stock-search list. New entries to the list include Cell Therapeutics, Hemispherx Biopharma, Vanda Pharmaceuticals and China Unicom Hong Kong.
A bull and a bear make their cases for whether a larger drug company will buy Vanda Pharmaceuticals.
Readers weigh in on Oculus Innovative Sciences, MAP Pharma, Human Genome and Hemispherx.
Too many red flags are flying over Hemispherx's chronic fatigue syndrome drug to be confident the FDA will approve it.
Itty bitty biotechs are big again, thanks to the H1N1 virus, cancer drug abstracts, and Vanda's recent success.
Readers want to know what's next for Sequenom after the data mishandling debacle, and what the prognosis is for Vanda.
Frank Curzio's guests include David Peltier, Adam Feuerstein, and Larsen Kusick.
Vanda is up 800% after the FDA approved its schizophrenia drug Fanapt, but investors still may find reason to buy the stock.
Movers roundup: Tenneco jumps on upgrade, Energy Conversion sinks on plans to halt production
The approval of Vanda's drug Fanapt for schizophrenia by the Food and Drug Administration sent shares of the company leaping more than 800% in Wednesday's after-hours trading session.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.